





started to cause serious problems in treatment<sup>9</sup>. Since antimicrobial resistance characteristics vary according to geographical regions and countries depending on the widespread use of antibiotics, spread of resistant strains and living conditions, each region should determine and monitor its own resistance status through surveillance studies<sup>10</sup>. The aim of this study was to determine the resistance rates of *S. pneumoniae* strains isolated in our laboratory to various antibiotics.

### METHODS

In this study, 80 *S.pneumoniae* strains isolated from clinical samples taken from patients of various age groups in central microbiology laboratory of our hospital between January 2014 and December 2019 were examined. In the identification of isolated pneumococcal strains, in addition to direct microscopic examination of clinical samples, culture on 5% sheep blood agar medium, macroscopic appearance of bacterial colonies and the presence of alpha hemolysis, Gram stain microscopic examination, catalase test, and optochin sensitivity test were used. Among the colonies, Gram-positive diplococci with alpha hemolysis, and optochin-sensitive colonies were further identified by Phoenix automated bacterial identification system (Becton Dickinson, USA). Sheep blood Mueller Hinton agar was used in the sensitivity test. The medium was incubated at 35 °C, with 5% CO<sub>2</sub> for 24 hours. Antimicrobial susceptibilities were determined by Kirby-Bauer disc diffusion method and evaluated according to The European Committee on Antimicrobial Susceptibility Testing (EUCAST) document<sup>11</sup>. Penicillin, cefotaxime and meropenem susceptibilities were examined by gradient test (E-TEST®, bioMérieux, France) and erythromycin, clindamycin, trimethoprim-sulfamethoxazole (TMP-SXT), levofloxacin, tetracycline, vancomycin and linezolid susceptibilities were examined by disc diffusion

(Oxoid™) method. Penicillin and meropenem breakpoints are different for meningitis and non-meningitis isolates according to EUCAST standards. Minimal inhibitory concentration (MIC) values were studied by gradient test. Strains isolated from meningitis infections were susceptible to penicillin with minimum inhibitory concentration (MIC) ≤ 0.06 µg / ml, and resistant with MIC > 0.06 µg / ml, while strains were susceptible to meropenem with MIC ≤ 0.25 µg / ml and strains with MIC > 0.6 µg / ml were considered resistant. Strains isolated from non-meningitis infections were susceptible to penicillin if MIC ≤ 0.06 µg / ml and resistant to if MIC ≥ 2 µg / ml; for meropenem strains were found to be susceptible if MIC ≤ 2 µg/ml and were resistant if MIC > 2 µg / ml. For cefotaxime strains with MIC ≤ 0.5 µg / ml were considered susceptible and strains with ≥ 2 µg / ml were considered resistant.

'*S.pneumoniae* ATCC 49619' was used as the standard strain for quality control.

Ethical approval: The study was approved by the local ethics committee (date: 21.01.2020 and number: 16).

### RESULTS

A total of 80 isolates including 32 blood samples, 29 respiratory samples, 10 cerebrospinal fluid (CSF), 5 vitreous, 4 pleural fluid and 1 abscess aspiration fluid were included in the study. Regarding the participants, 51 (63.7%) of the patients were male and 29 (36.3%) were female. The median age of the men were 41.8 years (range: 1-87) and women were 39.4 years (range: 0-91). Nine (90%) of the CSF isolates were male and one (10%) female, with a mean age of 47.4 years. Eight of these patients were hospitalized in the emergency department and two in the infectious disease clinic. Non-CSF isolates are obtained from patients in pediatric clinic, internal medicine, intensive care unit, infectious disease clinic, ophthalmology clinic,

hematology/oncology and other clinics, with a rate of 32.6%, 17.4%, 15.4%, 11.5%, 7.7%, 7.7%, and 7.7%, respectively.

In our study, it was observed that parenteral penicillin resistance was 70% in 7 CSF isolates and there was no resistance to cefotaxime and meropenem. The total resistance of 70 non-CSF isolates to penicillin was 41.4% (n: 29), moderate and high-level penicillin resistance rates were 21.4% (n: 15) and 20% (n:14), respectively. Cefotaxime resistance was detected in 2 (2.8%) of these isolates. Intermediate values were found in 2 (2.8%) isolates and remaining 66 (94.4%) isolates were susceptible. There was no meropenem resistance in non-CSF isolates. Resistance rates of erythromycin, clindamycin, trimethoprim-sulfamethoxazole, levofloxacin and tetracycline in all isolates were resistance rates of erythromycin, clindamycin, trimethoprim-sulfamethoxazole, levofloxacin and tetracycline in all isolates were 32.5%, 27.5%, 42.5%, 3.7% and 30%, respectively. There was no resistance to vancomycin and linezolid. In this study, the resistance rates of various antibiotics to *S. pneumoniae* strains in CSF and non-CSF isolates are shown in tables I and II.

**Table I:** The resistance rates of various antibiotics to *S. pneumoniae* strains in CSF samples (n:10)

Antibiotics	Number of resistant strains	Percentage of resistant strains (%)
Penicillin G	7	70
Cefotaxime	0	0
Meropenem	0	0
Erythromycin	4	40
Clindamycin	3	30
TMP-SXT	6	60
Tetracycline	2	20
Levofloxacin	0	0
Vancomycin	0	0
Linezolid	0	0

CSF: Cerebrospinal fluid, TMP-SXT: Trimethoprim-Sulfamethoxazole

**Table II.** The resistance rates of various antibiotics to *S. pneumoniae* strains in non-CSF samples (n: 70)

Antibiotics	Number of resistant strains	Percentage of resistant strains
Penicillin G*	29	41.4
Cefotaxime**	4	5.8
Meropenem	0	0
Erythromycin	22	31.4
Clindamycin	19	27.1
TMP-SXT	28	40
Tetracycline	22	31.4
Levofloxacin	3	4.2
Vancomycin	0	0
Linezolid	0	0

CSF: Cerebrospinal fluid, TMP-SXT: Trimethoprim-Sulfamethoxazole

\* In 14 (20%) of them high level, and in 15 (21.4%) of them moderate resistance; \*\*2 (2.9%) of them were resistant, 2 (2.9%) were having intermediate value in isolate.

In CSF isolates, the MIC values of antibiotics tested were 0.006 – 32µg/ml for penicillin, 0.008-0.5µg/ml for cefotaxime, and 0.004-0.25µg/ml for meropenem. All pneumococcal isolates were susceptible to cefotaxime and meropenem; but 7 of them were resistant to penicillin and only 3 of them was susceptible to penicillin.

In non-CSF isolates, the MIC values of antibiotics tested were 0.002 – 32µg/ml for penicillin, 0.006-4µg/ml for cefotaxime, and 0.002-0.5µg/ml for meropenem. All pneumococcal isolates were susceptible to meropenem; two were resistant and two were intermediate susceptible to cefotaxime while 14 of them were having high level resistance, 15 of them were having moderate level resistance to penicillin and 41 of them were susceptible to penicillin.

## DISCUSSION

*S. pneumoniae* is a member of the normal flora of the upper respiratory tract. Nasopharyngeal carriage, which varies according to age, season and environmental conditions, is important for the development of infection. It is a bacterium that can spread from the colonized region to various regions and may cause infections. *S. pneumoniae* is also one of the main causes of sepsis and septic shock<sup>12</sup>. The main findings of this study were; in CSF isolates very high (70%) resistance rates of *S. pneumoniae* to Penicillin G, followed by TMP-SXT (60%) and in non-CSF isolates, resistance rates of *S. pneumoniae* to Penicillin G was much lower with a 41.4% and followed by TMP-SXT (40%). On the other hand, absence of resistance of *S. pneumoniae* to Vancomycin and Linezolid were hopeful.

Although penicillin is the first choice in the treatment of pneumococcal infections, resistance to penicillin has become increasingly common all over the world. According to the "European Centers for Disease Control and Prevention (ECDC)" data, the highest penicillin resistance was observed in *S. pneumoniae* strains in Romania (46.7%) and in Spain (27.9%) and the lowest resistance was reported in Netherlands (2.1%) and Belgium (1.3%). Similarly, rates of resistance to erythromycin are also increasing, with Romania (48%) and Slovakia (41%) among the countries having the highest erythromycin resistance. According to this study, *S. pneumoniae* strains have been reported to be 18.8% non-penicillin-susceptible (moderate and high-level resistance) and erythromycin resistance was 16.1%<sup>13</sup>. "Centers for Disease Control and Prevention (CDC)" reported that in 2 897 invasive pneumococci isolates, sensitivity of penicillin, cefotaxime, erythromycin, TMP-SXT, tetracycline, levofloxacin and vancomycin were 96%, 97.9%, 70.7%, 82%, 88.7, 99.9%, and

100% according to The Clinical & Laboratory Standards Institute (CLSI) criteria<sup>14</sup>.

El Moujab et al. reviewed the national and local data about the pneumococcal epidemiology and resistance in the Middle East countries including Lebanon, Egypt, Saudi Arabia, Kuwait, Turkey, Palestine, United Arab Emirates, Oman, Bahrain, Iran and Jordan for areas related to, national, and made a compilation based on local data<sup>15</sup>. In this study, it was observed that antibiotic susceptibilities of invasive and non-invasive samples differed by country and years in different age groups. For example, the highest penicillin resistance in Saudi Arabia was 66% in clinical invasive isolates under 5 years of age based on national data and it was 90% in clinical invasive isolates under 15 years of age, based on local data. In the same study, in Turkey, between the years 2011-2013, covering all age groups, involving invasive and non-invasive samples, penicillin resistance was found as 61.9% in the table prepared based on national data. In general, when the above countries are evaluated together, the penicillin resistance is between 9.2 -90%; although different according to countries, the highest and lowest resistances for erythromycin, clindamycin, fluoroquinolone, TMP-SXT, vancomycin and tetracycline is 8.2-77%, 3.4-46%, 0-15.4%, 11.8-100%, 0-8%, and 31-77% %, respectively<sup>15</sup>. In their study with 258 *S. pneumoniae*, Ilki et al. found that, according to the 2008 CLSI criteria, penicillin resistance was 3.5%, medium and high level penicillin resistance was 3.1% and 0.4%, and resistance rates to erythromycin, tetracycline and TMP-SMX were found to be 19%, 26.8% and 49.2%, respectively<sup>16</sup>. In a study of Hasçelik et al. in Turkey, carried out with the participation of 14 different centers, in non-CSF isolates, intermediate and high level penicillin resistance was 21.7% and 16.8%, respectively while the penicillin resistance in CSF isolates was 52.6%, and the cefotaxime resistance was 5.3%, while

moderate sensitivity was found as 18.4%. The researchers shared that the sensitivities of the isolates were also different between the centers<sup>17</sup>. In the study conducted by Öksüz and Gürler, moderate resistance to penicillin G 2% and cefotaxime 3% was found in 100 isolates. Erythromycin resistance was reported in 25% of the strains isolated from invasive samples, 37% of the strains isolated from non-invasive samples at a total of 33%<sup>18</sup>. In another clinical study from our country, 80 clinical isolates recovered from 19 pediatric and 61 adult patients were analyzed, and the author reported that low level resistance to penicillin was determined in only 1 (1%) strain, while high level resistance wasn't present. In that study, TMP-SMX, erythromycin, chloramphenicol and ofloxacin resistance rates were reported as 56%, 27.5%, 9%, and 2.5%, respectively. All strains were found susceptible to vancomycin, linezolid and levofloxacin<sup>19</sup>. Söyletir et al. reported the results of the Survey of Antibiotic Resistance (SOAR) for respiratory tract infection pathogens collected in 2011-13 from Turkey and determined that among 333 isolates of *S. pneumoniae* tested; penicillin, erythromycin and cefuroxime resistance rates were 38%, 51% and 64.6%, respectively<sup>20</sup>. They also reported that, >90% of the isolates were susceptible to amoxicillin/clavulanic acid, ceftriaxone, levofloxacin and high-dose intravenous penicillin.

In a meta-analysis of 16 studies, Hosseini et al. reported the pooled prevalence of *S. pneumoniae* nasopharyngeal carriage as 18% among healthy children and the antibiotic resistance rates were 26%, 30% and 34% to penicillin, erythromycin and tetracycline, respectively<sup>21</sup>. In a recent review, Cherazard et al. reported that there has been a steady decline in susceptibility of *S. pneumoniae* to commonly used beta-lactams due to the genetic structural modification in penicillin-binding proteins<sup>22</sup>. In

the same review, the macrolide resistance was between 20% and 40%, clindamycin resistance was about 22%, TMP-SMX resistance was around 35%; while the fluoroquinolone resistance was still low. These data were also compatible with our results.

We sub-grouped the CSF and non-CSF isolates in this study, which was the main power of the study. However, there are some limitations that should be mentioned. First is the low number of isolates and secondly this study was performed in a single center and carrying the handicaps of this condition.

Based on the above data, the sensitivities of pneumococcal strains may be different between countries and even in different centers within the same country. In our study, penicillin resistance was found to be high in CSF isolates. This result shows us that penicillin is not suitable for meningitis. Absence of cefotaxime, meropenem, vancomycin and linezolid resistance in CSF isolates are pleasing. However, the low number of isolates can be seen as a disadvantage of this study. In non-CSF isolates, 5.8% of cefotaxime resistance (resistant and intermediate value) is compatible with that data from Turkey. Erythromycin is also a primary drug used in non-meningitis infections, but it has no role in treatment unless the strains are susceptible in antibiotic susceptibility tests. According to our data, we observed that levofloxacin has a higher percentage of susceptibility than other antimicrobials, and we may think that it is a viable option when antibiotics other than beta-lactam group are needed. In order to limit the spread of resistant pneumococcal strains, antibiotic treatments should be evaluated carefully; health policies should be developed in this direction regarding the prevention of unnecessary antibiotic use and improving vaccination programs.

**Ethics Committee Approval:** Ethical approval: The study was approved by the local ethics committee (date: 21.01.2020 and number: 16).

**Declaration of Conflicting Interests:** The authors declare that they have no conflict of interest.

**Financial Disclosure:** No financial support was received.

## REFERENCES

1. Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, microbiology, and pathogenesis. *Cold Spring Harb Perspect Med.*2013; 3: a010215.
2. O'Brien KL, Wolfson LJ, Watt J P, et al. Burden of disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global estimates. *Lancet.*2009; 374: 893–902.
3. Obaro S, Adegbola R. The pneumococcus: carriage, disease and conjugate vaccines. *J Med Microbiol.* 2002; 51: 98–104.
4. Mahon CR, Lehman DC, Manuselis G. *Textbook of diagnostic microbiology*, 4th edn. Saunders, 2010.
5. Donkor ES. Understanding the pneumococcus: transmission and evolution. *Front Cell Infect Microbiol.* 2013; 3: 7.
6. Bogaert D, de Groot R, Hermans PW. *Streptococcus pneumoniae* colonisation: the key to pneumococcal disease. *Lancet Infect Dis.*2004; 4: 144–54.
7. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. *Thorax.*2015; 70: 984–9.
8. Hansman D, Bullen MM. A resistant pneumococcus. *The Lancet.*1967; 290: 264–5.
9. Aslan G, Emekdaş G, Delialioğlu N, Bayer M. Kreşçocukları ve huzurevinde kalan yaşlılarda orofaringeal *Streptococcus pneumoniae* taşıyıcılığı ve izole edilen suşlarda penisiline direnç. *Türk Mikrobiyol Cem Derg.*2005; 35: 85-90.
10. Bayram A, Koçoğlu ME, Ekşi F, Balcı İ. Pnömonoklarda makrolidve florokinolonlara direnç. *Türk Mikrobiyol Cem Derg.*2005; 35: 284-90.
11. EUCAST Clinical Breakpoint Table Version 6.0. Valid From 2016-01-01. Basel: EUCAST, 2016. [http://www.eucast.org/clinical\\_breakpoints/](http://www.eucast.org/clinical_breakpoints/).
12. Kim L, McGee L, Tomczyk S, Beall B. Biological and epidemiological features of antibiotic resistant *Streptococcus pneumoniae* in pre- and post-conjugate vaccine eras: a United States perspective. *Clin Microbiol Rev.* 2016; 29: 525-52.
13. Antimicrobial resistance surveillance in Europe Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), 2014. <http://www.ecdc.europa.eu>
14. Centers for Disease Control and Prevention. 2017. Active bacterial core surveillance report, emerging infections program network, *Streptococcus pneumoniae* <http://www.cdc.gov/abcs/reportsfindings/survreports/spneu17.pdf>
15. El Moujaber G, Osman M, Rafei R, Dabboussi F, Hamze M. Molecular mechanisms and epidemiology of resistance in *Streptococcus pneumoniae* in the Middle East region. *J Med Microbiol.* 2017; 66: 847–58.
16. İlki A, Sağıroğlu P, Elgörmüş N, Söyletir G. Trends in antibiotic susceptibility patterns of *Streptococcus pneumoniae* and *Haemophilus influenzae* isolates: four years follow up. *Mikrobiyol Bul.* 2010; 44: 169-75.
17. Haşçelik G, Gürler N, Ceyhan M. Serotype distribution and antibiotic resistance among isolates of *Streptococcus pneumoniae* causing invasive pneumococcal disease in adults in Turkey: 2005-2015. *Int J Infect Dis.* 2016; 45: 91.
18. Öksüz L, Gürler N. Bir Üniversite hastanesinde yetişkin hastalardan izole edilen *Streptococcus pneumoniae* suşlarının serotip dağılımı ve antibiyotik direnci. *Mikrobiyol Bul.* 2017; 51: 195-208.
19. Akgün Karapınar DB. Determination of serotypes and antibiotic resistance in *Streptococcus pneumoniae*. *J Clin Anal Med.* 2015; 6: 443-7.

20. Soyletir G, Altinkanat G, Gur D, et al. Results from the survey of antibiotic resistance (SOAR) 2011-13 in Turkey. *J Antimicrob Chemother.* 2016; 71: 71-83.
21. Hosseini SM, Poorolajal J, Karami M, Ameri P. Prevalence of nasopharyngeal carriage of *Streptococcus pneumoniae* in Iran: A Meta-Analysis. *J Res Health Sci.* 2015; 15: 141-6.
22. Cherazard R, Epstein M, Doan TL, Salim T, Bharti S, Smith MA. Antimicrobial resistant *Streptococcus pneumoniae*: prevalence, mechanisms, and clinical implications. *Am J Ther.* 2017; 24: e361-9.